Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 5/20 | 0.50 |
| ▸ | ABL1 | P00519 | 3/20 | 0.50 |
| ▸ | BCR | P11274 | 2/20 | 0.50 |
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | PRKACG | P22612 | 1/20 | 0.48 |
| ▸ | PRKACB | P22694 | 1/20 | 0.48 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.47 |
| ▸ | YES1 | P07947 | 1/20 | 0.46 |
| ▸ | HCK | P08631 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12785351 | 0.90 | NEK1 (0.66) | NEK1SRCCDK2IGF1RCCNK | |
| SCHEMBL2158052 | 0.89 | NEK1 (0.53) | NEK1SRCCDK2CDK4IGF1R | |
| SCHEMBL1164419 | 0.87 | CDK1 (0.55) | NEK1SRCCDK2SYKIKBKB | |
| SCHEMBL12783961 | 0.86 | NPC1 (0.65) | NEK1SRCABL1BCRYES1 | |
| SCHEMBL12437998 | 0.85 | IGF1R (0.50) | NEK1SRCCDK2IGF1RSYK | |
| SCHEMBL18901334 | 0.83 | IGF1R (0.53) | NEK1SRCCDK2CDK4IGF1R | |
| SCHEMBL14050460 | 0.83 | IGF1R (0.50) | NEK1SRCCDK2IGF1RCCNK | |
| SCHEMBL12045459 | 0.82 | SRC (0.57) | NEK1SRCABL1IGF1REGFR | |
| SCHEMBL12783953 | 0.81 | AURKA (0.54) | NEK1IGF1RCCNKCDK13CDK12 | |
| SCHEMBL11339007 | 0.81 | IGF1R (0.69) | IGF1RSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2340248-B1 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | UNIV CALIFORNIA (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2340248-B1 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | UNIV CALIFORNIA (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-9382230-B2 | Methods and compositions for modulating Ire1, SRC and ABL activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382230-B2 | Methods and compositions for modulating Ire1, SRC and ABL activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382230-B2 | Methods and compositions for modulating Ire1, SRC and ABL activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150011575-A1 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-01-08 | — | — | US | disclosed |
| US-20150011575-A1 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-01-08 | — | — | US | disclosed |
| US-20150011575-A1 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-01-08 | — | — | US | disclosed |
| US-8815885-B2 | Methods and compositions for modulating IRE1, SRC, and ABL activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2464641-B1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMA (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20110319436-A1 | Methods and Compositions for Modulating IRE1, SRC, and ABL Activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319436-A1 | Methods and Compositions for Modulating IRE1, SRC, and ABL Activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319436-A1 | Methods and Compositions for Modulating IRE1, SRC, and ABL Activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-29 | — | — | US | disclosed |
| EP-2340248-A2 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | The Regents of the University of California (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2010031056-A2 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010031056-A2 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011575-A1 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | XBP1, SRC, HSP90B1 | NEK1 1906/4885SRC 2/4885ABL1 14/4885 |
| US-20110319436-A1 | Methods and Compositions for Modulating IRE1, SRC, and ABL Activity | XBP1, SRC, HSP90B1 | NEK1 1906/4885SRC 2/4885ABL1 14/4885 |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | NEK1 960/4885SRC 4218/4885ABL1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.